Seeking qualified laboratories worldwide to perform quantitative phosphorylated tau-217 (p-tau217) and/or phosphorylated tau-181 (p-tau181) testing on human finger-prick dried plasma spot (DPS) samples. The project will begin with a feasibility evaluation focused on analytical sensitivity, reproducibility, and cost-effective processing using existing laboratory methods and infrastructure. Successful evaluation may lead to recurring sample testing.
Initial volume: Approximately 25 specimens, potentially increasing to 25–100 specimens per month and higher volumes. All volumes are estimates, not commitments.
Sample collection: Finger-prick DPS samples collected using compact plasma-separation cards and consolidated for shipment from the United States.
Target analytes: p-tau217 preferred; p-tau181 accepted as an alternative or complementary analyte.
Method preference: Established DPS assays or methods requiring limited transfer or adaptation, rather than extensive assay development.
Analytical platform: Simoa or another sufficiently sensitive platform suitable for DPS extracts.
Experience with p-tau217 or p-tau181 analysis, distinguishing finger-prick DPS, venous-derived DPS, and liquid plasma testing.
Recommended collection cards, sample volume, extraction procedures, and analytical instrumentation.
Available analytical performance data, including quantification limits, repeatability, recovery, and sample failure rates.
Storage and shipping requirements, acceptable collection-to-analysis intervals, and conditions for receiving specimens from the United States.
Outstanding feasibility or method-transfer requirements, estimated timelines, and earliest pilot availability.
Preliminary setup costs and all-inclusive per-specimen pricing for 25, 50, and 100 specimens per month, plus indicative pricing for larger volumes. Identify minimum batch charges and additional QC, repeat-analysis, or reporting fees.
Performing laboratory location, subcontractor involvement, and applicable accreditations.
This request is for research feasibility and analytical method evaluation, not immediate clinical diagnostic use. Laboratories without clinical certification may respond but should disclose accreditation status and relevant limitations. Clinical-use requirements will be evaluated separately if the project progresses.
Preference will be given to laboratories offering a cost-efficient, nonexclusive partnership with demonstrated technical capabilities, transparent preliminary pricing, and a practical path to higher testing volumes.
Length of ServiceRecurring service indefinitely
Number of Samples25
Can you help?